Effect of Peer-led Educational Intervention on Treatment Outcomes Among Adults With Drug-suscepti… (NCT07387601) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Effect of Peer-led Educational Intervention on Treatment Outcomes Among Adults With Drug-susceptible Pulmonary Tuberculosis in South Omo and Ari Zone, Southern Ethiopia
250 participantsStarted 2026-02-24
Plain-language summary
The study might come up with valuable findings to address poor treatment outcome, poor quality of life, disability score and depressive symptoms. The findings may also be decreased health professional workload. The findings would be supportive evidences for policy makers, program managers, to clinician as well as the patients themselves and for other researchers. The study may help to promote and maintain good treatment outcome for the patients in the study area as well as the country. The findings will also be used for teaching \& learning purposes in educational \& training programs.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Adults with new drug-susceptible pulmonary TB who will be diagnosed in bacteriological diagnostic methods
* not participating in similar study,
* mentally capable to provide consent,
* physically capable of following the intervention.
Exclusion Criteria:
* Seriously ill patients at the time of screening or enrollment
* Tuberculosis patients with a known plan to be transferred out of the study sites
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
treatment success rate
Timeframe: the primary outcome will be measured at the end of 6 months i.e after July 24/2026
Trial details
NCT IDNCT07387601
SponsorBahirdar University
Sponsor typeNETWORK
Study typeINTERVENTIONAL
Primary completion2026-07-12
Contact for this trial
Moges Getie Workie, MPH in Epidemiology and PhD st